Abstracts Archive - Page 2208 of 2607 - ACR Meeting Abstracts

Abstract Number: 387 • 2014 ACR/ARHP Annual Meeting
Levels of IgG Autoantibodies to Oxidation-Associated MDA Neo-Determinants Are a Biomarker for Systemic Inflammation and Disease Activity in SLE and RA
Caroline Grönwall¹, Lelise Getu², Jeffrey D. Greenberg³, Robert M. Clancy⁴ and Gregg J. Silverman¹, ¹Medicine, New York University School of Medicine, New York, NY, ²New York University School of Medicine, New York, NY, ³Rheumatology, New York University School of Medicine, New York, NY, ⁴Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose Monitoring disease activity in patients with autoimmune rheumatic disease is an essential part of clinical care. Highly reactive malondialdehyde (MDA) arise from reactive oxygen…
Abstract Number: 386 • 2014 ACR/ARHP Annual Meeting
Association of Pharmacogenetic Markers with Treatment Response in Patients with Rheumatoid Arthritis
Ute I. Schwarz¹, Janet E. Pope², Edward Keystone³, Boulos Haraoui⁴, Carter Thorne⁵, Yun-Hee Choi¹, Melanie Poulin-Costello⁶, Nabil Bayan⁷ and Richard B. Kim¹, ¹Western University, London, ON, Canada, ²Medicine, Western University, London, ON, Canada, ³Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁴University of Montreal Hospital Centre, Montreal, QC, Canada, ⁵Southlake Regional Health Centre, Newmarket, ON, Canada, ⁶Biostatistics, Amgen Canada Inc., Mississauga, ON, Canada, ⁷Amgen Canada Inc., Mississauga, ON, Canada
Background/Purpose : In the CAnadian Methotrexate and Etanercept Outcome Study (CAMEO) continued therapy with etanercept (ETN) and methotrexate (MTX) led to better outcomes at month…
Abstract Number: 385 • 2014 ACR/ARHP Annual Meeting
Validation of a Prognostic Model to Predict Structural Damage Assessed By X-Ray in Patients with RA Using MRI Data from a Clinical Trial
EA Alemao¹, S Joo², S Banerjee¹, P Allison³, P Emery⁴, M Weinblatt⁵ and Katherine Liao⁶, ¹Bristol-Myers Squibb, Princeton, NJ, ²Bristol-Myers Squibb, Hopewell, NJ, ³University of Pennsylvania, Philadelphia, PA, ⁴University of Leeds, Leeds, United Kingdom, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: We developed and validated a prognostic model for rapid radiographic progression (RRP) using X-ray data to identify RA patients (pts) at risk of structural…
Abstract Number: 380 • 2014 ACR/ARHP Annual Meeting
In Palindromic Rheumatism, Older Age, Shorter Interval Between Attacks and Positive Anti-CCP Antibodies May Predict Progression to RA
Masatoshi Hayashi^1,2, Jackie L. Nam³, Laura Hunt³, Elizabeth Hensor³, Toshihisa Kanamono⁴, Toshihisa Kojima⁵, Naoki Ishiguro⁵ and Paul Emery⁶, ¹NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds., Leeds, United Kingdom, ²5-22-1 Wakasato, Nagano Red Cross Hospital, Nagano, Japan, ³NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Departments of Orthopedic surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, ⁵Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁶NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds., United Kingdom, Leeds, United Kingdom
Background/Purpose Palindromic rheumatism (PR) is a clinical syndrome characterised by episodes of joint swelling that settle spontaneously. A proportion of patients with PR progress and…
Abstract Number: 370 • 2014 ACR/ARHP Annual Meeting
Double Positivity of RA Serologies More Prevalent Yet Associated with Clinical Response in Ethnic Minority Patients with Rheumatoid Arthritis
Mercedes Quinones¹, Sharon Dowell², Ignacio Garcia-Valladares³, Gail S. Kerr⁴, Christopher Swearingen⁵, Luis R. Espinoza⁶, Yusuf Yazici⁷, Edward L. Treadwell⁸, Theresa Lawrence Ford⁹, Yvonne Sherrer¹⁰, Angelia Mosley-WIlliams¹¹, Rodolfo Perez Alamino¹², Chunqiao Luo¹³, Akgun Ince¹⁴, Adrian Godoy² and John Amatruda¹⁵, ¹Division of Rheumatology, Howard University Hospital, Washington, DC, ²Division of Rheumatology, Howard University, Washington, DC, ³Immunology and Rheumatology, Hospital General de Occidente, Zapopan, Jal., Mexico, ⁴Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ⁵Pediatrics and Biostatistics, University of Arkansas, Little Rock, AR, ⁶Medicine-Section of Rheum, LSU Medical Center, New Orleans, LA, ⁷Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁸Dept Medicine Div of Rheum, East Carolina University, Greenville, NC, ⁹North Georgia Rheumatology Group, PC, Lawrenceville, GA, ¹⁰Rheum/Immunology, Centre Rheum Immunol Arthritis, Fort Lauderdale, FL, ¹¹Rheumatology, Detroit VAMC, Detroit, MI, ¹²internal Medicine, LSUHSC, New Orleans, LA, ¹³University of Arkansas for Medical Sciences, Little Rock, AR, ¹⁴Arthitis Consultants Inc, St. Louis University, St. Louis, MO, ¹⁵Rheumatology, Howard University, Washington, DC
Double Positivity of RA Serologies More Prevalent But Associated with Clinical Response in a Diverse Ethnic Cohort with Rheumatoid ArthritisBackground/Purpose: The presence of both the…
Abstract Number: 369 • 2014 ACR/ARHP Annual Meeting
Validation of Snapshot, a Rheumatoid Arthritis Assessment Tool, Against CDAI, DAS28 (ESR), and DAS28 (CRP) in Canadian Patients with Rheumatoid Arthritis
William G Bensen¹, Wynn Bensen², Melissa Deamude², Cynthia Mech³, Robert Bensen⁴, Arthur N. Lau⁵ and Alpesh Shah⁶, ¹St Josephs Hospital and McMaster University, Hamilton, ON, Canada, ²Dr William G Bensen Medicine Professional Corp, Rheumatology Health Team, Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, ³Dr. William G. Bensen, Rheumatology Health Team, Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, ⁴Rheumatology Health Team, Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, ⁵Rheumatology and Clinical Epidemiology, Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ⁶Epidemiology and Biostatistics, University of Western Ontario, MSc in Clinical Epidemiology, University of Western Ontario, London, ON, Canada
Background/Purpose: Measuring disease activity in Rheumatoid Arthritis (RA) remains an elusive goal. Both DAS and CDAI have an inherent weakness because similar numbers can result…
Abstract Number: 368 • 2014 ACR/ARHP Annual Meeting
Serum C1M Level Predicts Disease Progression and Early Treatment Efficacy in Rheumatoid Arthritis
Anne C. Bay-Jensen¹, Anne Sofie Siebuhr², Inger Byrjalsen³, Claus Christiansen³ and Morten Asser Karsdal¹, ¹Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ²Rheumatology, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ³Nordic Bioscience, Herlev, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is partly characterized by joint destruction. Personalized health care is needed in RA to enable i) prediction of those patients that…
Abstract Number: 367 • 2014 ACR/ARHP Annual Meeting
In Early Rheumatoid Arthritis Patients with Non-Response to Methotrexate Monotherapy the Change in Multi-Biomarker Disease Activity Score Is Differentially Associated with Subsequent Response to Non-Biological Versus Biological Therapy
Karen Hambardzumyan¹, R.J. Bolce², Saedis Saevarsdottir³, Kristina Forslind⁴, Ingemar F. Petersson⁵, Pierre Geborek⁶, Eric H. Sasso², David Chernoff², Scott Cruickshank⁷ and Ronald F. van Vollenhoven⁸, ¹ClinTRID, the Karolinska Institute, Stockholm, Sweden, ²Crescendo Bioscience Inc., South San Francisco, CA, ³Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁵Lund University, Lund, Sweden, ⁶Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, ⁷Scott Cruickshank and Associates, Inc., Santa Barbara, CA, ⁸Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden
Background/Purpose For patients with early RA (eRA), methotrexate (MTX) is recommended as first-line treatment and in non-responders both the addition of conventional non-biological disease modifying…
Abstract Number: 366 • 2014 ACR/ARHP Annual Meeting
Soluble 4-1BB Is a Marker of Joint Involvement and Disease Activity in Rheumatoid Arthritis
Morten Aagaard Nielsen¹, Thomas Andersen², Kristian Stengaard-Pedersen³, Kim Hoerslev-Petersen⁴, Merete Lund Hetland⁵, Peter Junker⁶, Mikkel Ostergaard⁷, Malene Hvid¹ and Bent Deleuran⁸, ¹Department of Biomedicine, Aarhus University, Aarhus, Denmark, ²Dept. of Biomedicine, Aarhus University, Aarhus, Denmark, ³Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁴Rheumatology, Research Unit at King Christian X Hospital for Rheumatic Diseases, Graasten, Denmark, ⁵DANBIO, Center for Rheumatology and Spine Diseases, Glostrup University Hospital, Glostrup, Denmark, Glostrup, Denmark, ⁶University of Southern Denmark, Odense, Denmark, ⁷Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, ⁸Dept. of Rheumatology, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose 4-1BB is induced on T cells after antigen encounter and promotes clonal expansion and accumulation of high numbers of antigen-specific effector-type T cells primarily…
Abstract Number: 365 • 2014 ACR/ARHP Annual Meeting
Differential Relative Contribution of Individual Components on DAS28 over Time: An Analysis from the Prospective, Observational, Biological Treatment Registry Across Canada
Denis Choquette¹, Dalton Sholter², Isabelle Fortin³, Michael Starr⁴, Carter Thorne⁵, Milton Baker⁶, Regan Arendse⁷, Philip Baer⁸, Michel Zummer⁹, Jude Rodrigues¹⁰, Maqbool Sheriff¹¹, Emmanouil Rampakakis¹², John S. Sampalis¹², Francois Nantel¹³, Allen J Lehman¹⁴, Susan Otawa¹⁴ and May Shawi¹³, ¹Rheumatology, Notre Dame Hospital, Montreal, QC, Canada, ²University of Alberta, Edmonton, AB, Canada, ³Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, ⁴Montreal General Hospital, Montreal, QC, Canada, ⁵Southlake Regional Health Centre, Newmarket, ON, Canada, ⁶University of Victoria, Victoria, BC, Canada, ⁷University of Saskatchewan, Saskatoon, SK, Canada, ⁸Private Practice, Scarborough, ON, Canada, ⁹Université de Montréal, Montreal, QC, Canada, ¹⁰Clinical Research and Arthritis Centre, Windsor, ON, Canada, ¹¹Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ¹²JSS Medical Research, Montreal, QC, Canada, ¹³Janssen Inc., Toronto, ON, Canada, ¹⁴Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose DAS28 is an important outcome for clinical research and practice assisting with therapeutic decisions. The main contributors to DAS28 are joint tenderness and acute-phase…
Abstract Number: 364 • 2014 ACR/ARHP Annual Meeting
In Early Rheumatoid Arthritis, the Multi-Biomarker Disease Activity Score at Different Time-Points Is Predictive of Subsequent Radiographic Progression
Karen Hambardzumyan¹, R.J. Bolce², Saedis Saevarsdottir*³, Kristina Forslind⁴, Ingemar F. Petersson⁵, Pierre Geborek⁶, Eric H. Sasso², David Chernoff², Scott Cruickshank⁷ and Ronald F. van Vollenhoven⁸, ¹ClinTRID, the Karolinska Institute, Stockholm, Sweden, ²Crescendo Bioscience Inc., South San Francisco, CA, ³Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁵Lund University, Lund, Sweden, ⁶Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, ⁷Scott Cruickshank and Associates, Inc., Santa Barbara, CA, ⁸Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden
Background/Purpose The prediction of radiographic progression in early rheumatoid arthritis (eRA) patients is important for optimal treatment. We previously demonstrated that a multi-biomarker disease activity…
Abstract Number: 363 • 2014 ACR/ARHP Annual Meeting
Increased Prevalence of Plasma Anti-Nuclear, Anti-SSA, and Connective Tissue Disease Associated Antibodies in African American Patients with Rheumatoid Arthritis
Rayford R. June¹, Douglas P. Landsittel², Bruce Rabin³, S. Louis Bridges Jr.⁴, CLEAR Investigators⁵, TEAR Investigators⁵, Thomas A. Medsger Jr.⁶ and Larry W. Moreland⁶, ¹Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Medicine, Biostatistics and Clinical and Translational Science, University of Pittsburgh, Center for Health Care Research Data Center, Pittsburgh, PA, ³Pathology, Division of Clinical Immunopathology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose African American (AA) patients with rheumatoid arthritis (RA) have been shown to have worse disability scores, increased disease activity scores, and reduced use of…
Abstract Number: 362 • 2014 ACR/ARHP Annual Meeting
14-3-3η Early RA Biomarkers: Does Seronegative RA Exist?
Dirkjan van Schaardenburg¹, Walter P. Maksymowych², Maarten Boers³, Samina Turk⁴, Mairead Murphy⁵ and Anthony Marotta⁶, ¹Dr Jan van Breemenstraat 2, Reade, Amsterdam, Netherlands, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Deapartment of Epidemiology and Biostatistics, Jan van Breemen Research Institute/Reade, Amsterdam, Netherlands, ⁴Reade, Amsterdam, Netherlands, ⁵Augurex Life Sciences Corp., North Vancouver, BC, Canada, ⁶1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada
Background/Purpose RF and ACPA are used for early diagnosis and in prediction models for the risk of RA development in arthralgia patients. There remains a…
Abstract Number: 361 • 2014 ACR/ARHP Annual Meeting
Citrullinated 14-3-3η Antibodies Are Specific for Early and Established RA and Are Complementary to ACPA
Anthony Marotta¹, Dirkjan van Schaardenburg², Gilles Boire³, Désirée van der Heijde⁴, Robert Landewé⁵, Maarten Boers⁶, C.F. Allaart⁷, Mairead Murphy⁸, Samina Turk⁹, Vivian P. Bykerk¹⁰, Edward Keystone¹¹, Katherine A. Siminovitch¹¹ and Walter P. Maksymowych¹², ¹1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada, ²Dr Jan van Breemenstraat 2, Reade, Amsterdam, Netherlands, ³Rheumatology Division, CHUS - Sherbrooke University, Sherbrooke, QC, Canada, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁶Deapartment of Epidemiology and Biostatistics, Jan van Breemen Research Institute/Reade, Amsterdam, Netherlands, ⁷Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁸Augurex Life Sciences Corp., North Vancouver, BC, Canada, ⁹Reade, Amsterdam, Netherlands, ¹⁰Divison of Rheumatology, Hospital for Special Surgery, New York, NY, ¹¹Mount Sinai Hospital, Toronto, ON, Canada, ¹²Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose Citrullination is a post-translational modification whereby arginine (Arg) is deiminated by PAD enzymes to form citrulline (Cit). In RA, current ACPA assays measure the…
Abstract Number: 360 • 2014 ACR/ARHP Annual Meeting
88% of Recent Onset Polyarthritis Patients Are Positive for 14-3-3η Markers and 14-3-3η Auto-Antibodies Inform a Favourable Prognosis
Gilles Boire¹, Nathalie Carrier², Artur Jose de Brum-Fernandes³, Patrick Liang⁴, Ariel Masetto⁵, Yuan Gui⁶, Mairead Murphy⁶, Walter P. Maksymowych⁷ and Anthony Marotta⁸, ¹Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ²Rheumatology, Universite de Sherbrooke, Sherbrooke, QC, Canada, ³Department of Medicine, Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁴Rheumatology Division, CHUS, Sherbrooke, QC, Canada, ⁵Rheumatology, CHUS, Fleurimont, QC, Canada, ⁶Augurex Life Sciences Corp., North Vancouver, BC, Canada, ⁷Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁸1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada
Background/Purpose The 14-3-3η protein has been described as a mechanistic marker that is detectable in serum during the very early stages of RA development. A…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].